TGF-β receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells

被引:145
作者
Watabe, T
Nishihara, A
Mishima, K
Yamashita, J
Shimizu, K
Miyazawa, K
Nishikawa, S
Miyazono, K
机构
[1] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan
[2] Kyoto Univ, Inst Frontier Med Sci, Stem Cell Res Ctr, Lab Stem Cell Differentiat,Sakyo Ku, Kyoto 6068509, Japan
[3] Kirin Brewery Co Ltd, Div Pharmaceut, Takasaki, Gumma 3701295, Japan
[4] RIKEN, Ctr Dev Biol, Lab Stem Cell Biol, Chuo Ku, Kobe, Hyogo 6500047, Japan
[5] Inst Canc Res, Japanese Fdn Canc Res, Dept Biochem, Tokyo 1708455, Japan
关键词
vascular progenitor cells; endothelial development; tight junction; claudin-5; SB-431542;
D O I
10.1083/jcb.200305147
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Recent findings have shown that embryonic vascular progenitor cells are capable of differentiating into mural and endothelial cells. However, the molecular mechanisms that regulate their differentiation, proliferation, and endothelial sheet formation remain to be elucidated. Here, we show that members of the transforming growth factor (TGF)-beta superfamily play important roles during differentiation of vascular progenitor cells derived from mouse embryonic stem cells (ESCs) and from 8.5-days postcoitum embryos. TGF-beta and activin inhibited proliferation and sheet formation of endothelial cells. Interestingly, SB-431542, a synthetic molecule that inhibits the kinases of receptors for TGF-beta and activin, facilitated proliferation and sheet formation of ESC-derived endothelial cells. Moreover, SB-431542 up-regulated the expression of claudin-5, an endothelial specific component of tight junctions. These results suggest that endogenous TGF-beta/activin signals play important roles in regulating vascular growth and permeability.
引用
收藏
页码:1303 / 1311
页数:9
相关论文
共 26 条
[1]   Making sense of latent TGFβ activation [J].
Annes, JP ;
Munger, JS ;
Rifkin, DB .
JOURNAL OF CELL SCIENCE, 2003, 116 (02) :217-224
[2]   Isolation of putative progenitor endothelial cells for angiogenesis [J].
Asahara, T ;
Murohara, T ;
Sullivan, A ;
Silver, M ;
vanderZee, R ;
Li, T ;
Witzenbichler, B ;
Schatteman, G ;
Isner, JM .
SCIENCE, 1997, 275 (5302) :964-967
[4]   Identification of novel inhibitors of the transforming growth factor β1 (TGF-β1) type 1 receptor (ALK5) [J].
Callahan, JF ;
Burgess, JL ;
Fornwald, JA ;
Gaster, LM ;
Harling, JD ;
Harrington, FP ;
Heer, J ;
Kwon, C ;
Lehr, R ;
Mathur, A ;
Olson, BA ;
Weinstock, J ;
Laping, NJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (05) :999-1001
[5]   Mechanisms of angiogenesis and arteriogenesis [J].
Carmeliet, P .
NATURE MEDICINE, 2000, 6 (04) :389-395
[6]   Combinatorial effects of Flk1 and Tal1 on vascular and hematopoietic development in the mouse [J].
Ema, M ;
Faloon, P ;
Zhang, WL ;
Hirashima, M ;
Reid, T ;
Stanford, WL ;
Orkin, S ;
Choi, K ;
Rossant, J .
GENES & DEVELOPMENT, 2003, 17 (03) :380-393
[7]   Blood vessel formation: What is its molecular basis? [J].
Folkman, J ;
DAmore, PA .
CELL, 1996, 87 (07) :1153-1155
[8]   Balancing the activation state of the endothelium via two distinct TGF-β type I receptors [J].
Goumans, MJ ;
Valdimarsdottir, G ;
Itoh, S ;
Rosendahl, A ;
Sideras, P ;
ten Dijke, P .
EMBO JOURNAL, 2002, 21 (07) :1743-1753
[9]  
Goumans MJ, 2000, INT J DEV BIOL, V44, P253
[10]   SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 [J].
Inman, GJ ;
Nicolás, FJ ;
Callahan, JF ;
Harling, JD ;
Gaster, LM ;
Reith, AD ;
Laping, NJ ;
Hill, CS .
MOLECULAR PHARMACOLOGY, 2002, 62 (01) :65-74